Bacteremia in lung transplant recipients in the current era

American Journal of Transplantation

Volumn 6, Issue 12, 2006, Pages 3000-3007

  Husain, S ^a   Chan, K M ^b   Palmer, S M ^c   Hadjiliadis, D ^d   Humar, A ^e   McCurry, K R ^f   Wagener, M M ^a   Singh, N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bacteremia; Bacterial infections; Lung transplants

Indexed keywords

AZATHIOPRINE; AZTREONAM; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COLISTIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; T LYMPHOCYTE ANTIBODY; TOBRAMYCIN; TSUKUBAENOLIDE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR SELECTION; FEMALE; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 33751178633     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01565.x     Document Type: Article

References (26)

1. Palmer SM, Alexander BD, Sanders LL et al. Significance of blood stream infection after lung transplantation: Analysis in 176 consecutive patients. Transplantation 2000; 69: 2360-2366.
2. Griffith B, Hardesty R, Armitage J, Hattier B, Keenan R. A decade of lung transplantation. Ann Surg 1993; 218: 310-320.
3. Pietrantoni C, Minai OA, Yu NC et al. Respiratory failure and sepsis are the major causes of ICU admissions and mortality in survivors of lung transplants. Chest 2003; 123: 504-509.
4. Donnelly JP. Bacterial complications of transplantation: diagnosis and treatment. J Antimicrob Chemother 1995; 36: 59-72.
5. McClean K, Kneteman N, Taylor G. Comparative risk of bloodstream infection in organ transplant recipients. Infect Cont Hosp Epid 1994; 15: 582-584.
6. Danziger-Isakov LA, Sweet S, Delamorena M, Huddleston CB, Mendeloff E, Debaun MR. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 2005; 24: 324-330.
7. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003; 3: 156-161.
8. Meier-Kriesche H-U, Li S, Gruessner RWG et al. Immunosuppression: Evolution in practice and trends 1994-2004. Am J Transplant 2006; 6: 1111-1131.
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions of nosocomial infections. Am J Infect Control 1988; 16: 128-140.
10. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transplant 2000; 6: 54-61.
11. Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: A longitudinal study of antimicrobial susceptibility patterns. Liver Transplant 2001; 7: 22-26.
12. Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant Gram-negative bacilli in a long-term-care facility: A case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997; 18: 809-813.
13. Yu V L, Chiou CCC, Feldman C et al. (for the International Pneumococcal Study Group). An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003; 37: 230-237.
14. Halloran P F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
15. Rodriguez C, Muñoz P, Rodriquez-Créixems M, Yañez JF, Palomo J, Bouza E. Bloodstream infections among heart transplant recipients. Transplantation 2006; 81: 384-391.
16. Kotloff RM, Ajua.VN. Medical complications of lung transplantation. Eur Respir J 2004; 23: 334-342.
17. Rocha PN, Rocha AT, Scott M, Palmer R, Davis D, Smith SR. Acute renal failure after lung transplantation: Incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005; 5: 1469-1476.
18. Ishani A, Erturk S, Hertz MI, Mattas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 2228-2234.
19. Haupt R, Romannengo M, Fears T et al. Incidence of septicemia and invasive mycoses in children undergoing treatment for solid tumours: A 12-year experience at a single Italian institution. Eur J Cancer 2001; 37: 2413-2419.
20. Silveira FP, Marcos A, Kwak EJ et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: No evidence of occurrence of organisms typically asosciated with profound T cell depletion. J Infect 2006; Jan 2; E-pub ahead of print.
21. Munoz-Price LS, Slifkin M, Ruthazer R et al. The clinical impact of ganciclovir prophylaxis on occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39: 293-299.
22. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 1997; 175: 901-904.
23. Neyts J, Meerbach A, McKenna P, DeClerq E. Use of yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infection. Antiviral Res 1996; 30: 125-132.
24. Wade JJ, Rolando N, Hallar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: An analysis of 284 patients. Hepatology 1995; 21: 1328-1366.
25. Kolleff MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among criticall ill patients. Chest 1999; 115: 462-474.
26. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar AE, Jimenez-Jimenez FJ, Perez-Paredes C, Orti-Leyba C. Impact on the outcome of adequate empirical antibiotherapy in patients admitted to the ICU by sepsis. Crit Care Med 2003; 31(12): 2742-2751.